Financing will advance its musculoskeletal product through a clinical proof of activity trial as well as continue the discovery and development of its ongoing pipeline of microbial-based products for human health and well-being. CAMBRIDGE, Mass., October 19, 2020-- Solarea Bio, a biotech company based in Cambridge, MA developing microbial-based solutions to aid human health, announced today it has raised $11.2M in a Series A financing led by S2G Ventures and Bold Capital Partners, along with continued investment from Viking Global and additional investment from the Gisev Family Office as a syndicate investor.